PMID- 31285875
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231012
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 11
IP  - 5
DP  - 2019 May
TI  - A retrospective study of low-dose apatinib combined with S-1 in patients with 
      advanced non-small cell lung cancer.
PG  - 1831-1837
LID - 10.21037/jtd.2019.05.33 [doi]
AB  - BACKGROUND: The current regimens for advanced non-small cell lung cancer (NSCLC) 
      patients are deficient due to failings in standard treatments. This retrospective 
      study aimed to assess the efficacy and safety of low-dose apatinib in combination 
      with S-1 therapy in a NSCLC setting. METHODS: In this retrospective study, 
      advanced NSCLC patients who failed standard treatment in Changzhou Cancer 
      Hospital of Soochow University were screened for eligibility. Progression-free 
      survival (PFS) was set as the primary endpoint. Overall response rate (ORR), 
      disease control rate (DCR), overall survival (OS), and the safety profile were 
      considered to be the secondary endpoints. RESULTS: A total of 31 eligible 
      patients were included. The median PFS (mPFS) was 102 days (95% CI: 57-147 days). 
      ORR was achieved in 7 patients (22.6%; 95% CI: 11.1-38.2%) and DCR was maintained 
      in 23 patients (74.2%; 95% CI: 58.2-86.5%). The median OS (mOS) was 422 days (95% 
      CI: 148-696 days). Patients with a history of smoking tended to have a shorter OS 
      without significant differences (HR =4.105, 95% CI: 0.874-19.288, P=0.074). 
      Treatment-related grade III toxicity was observed in 5 patients (16%) and common 
      grade I or II adverse events (AEs) were fatigue (42%), hypertension (32%), and 
      hand-foot-skin reaction (23%). CONCLUSIONS: Combination of low-dose apatinib and 
      S-1 could be an effective and tolerable choice for advanced NSCLC patients who 
      are unable to benefit from standard treatment; however, further exploration in 
      larger clinical trials is needed.
FAU - Zhou, Tong
AU  - Zhou T
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Wu, Changling
AU  - Wu C
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Zhang, Changsong
AU  - Zhang C
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Li, Peng
AU  - Li P
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Dong, Huajie
AU  - Dong H
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Zhou, Xiaoyue
AU  - Zhou X
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Lu, Hongjun
AU  - Lu H
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Qi, Chuang
AU  - Qi C
AD  - The Medical Department, 3D Medicines Inc., Shanghai 200000, China.
FAU - Ling, Yang
AU  - Ling Y
AD  - Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, 
      Changzhou 213000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC6588741
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - S-1
OT  - apatinib
OT  - combination therapy
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2019/07/10 06:00
MHDA- 2019/07/10 06:01
PMCR- 2019/05/01
CRDT- 2019/07/10 06:00
PHST- 2019/07/10 06:00 [entrez]
PHST- 2019/07/10 06:00 [pubmed]
PHST- 2019/07/10 06:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - jtd-11-05-1831 [pii]
AID - 10.21037/jtd.2019.05.33 [doi]
PST - ppublish
SO  - J Thorac Dis. 2019 May;11(5):1831-1837. doi: 10.21037/jtd.2019.05.33.